Evidence map›Paper›PMID 32958720›Full record

ArticleAntimicrobial agents and chemotherapy2020

Developing New Drugs for Mycobacterium tuberculosis Therapy: What Information Do We Get from Preclinical Animal Models?

G L Drusano, Brandon Duncanson, C A Scanga, S Kim, S Schmidt, M N Neely, W M Yamada, Michael Vicchiarelli, C A Peloquin, Arnold Louie

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

G L DrusanoInstitute for Therapeutic Innovation, College of Medicine, University of Florida, Gainesville, Florida, USA gdrusano@ufl.edu.ORCID 0000-0001-9162-7332
Brandon DuncansonInstitute for Therapeutic Innovation, College of Medicine, University of Florida, Gainesville, Florida, USA.
C A ScangaDepartment of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
S KimCenter for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, Gainesville, Florida, USA.ORCID 0000-0002-9179-0735
S SchmidtCenter for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
M N NeelyUniversity of Southern California, Los Angeles, California, USA.
W M YamadaUniversity of Southern California, Los Angeles, California, USA.
Michael VicchiarelliInstitute for Therapeutic Innovation, College of Medicine, University of Florida, Gainesville, Florida, USA.
C A PeloquinCenter for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, Gainesville, Florida, USA.ORCID 0000-0001-9002-7052
Arnold LouieInstitute for Therapeutic Innovation, College of Medicine, University of Florida, Gainesville, Florida, USA.
University of Florida · USUniversity of Southern California · USUniversity of Pittsburgh · US

Funding

Optimizing Combination Therapy to Accelerate Clinical Cure of TuberculosisP01AI123036 · NIAID · UNIVERSITY OF FLORIDA · PI FLYNN, JOANNE L. · 2016 to 2020
$12.0M
NIAID NIH HHS P01 AI123036
6 · The paper itself

Abstract

Preclinical animal models of infection are employed to develop new agents but also to screen among molecules to rank them. There are often major differences between human pharmacokinetic (PK) profiles and those developed by animal models of infection, and these may lead to substantial differences in efficacy relative to that seen in humans. Linezolid is a repurposed agent employed to great effect for therapy of

Indexed as

Mycobacterium tuberculosisPharmaceutical PreparationsTuberculosisAnimalsAntitubercular AgentsMiceModels, AnimalProspective StudiesAntitubercular AgentsPharmaceutical Preparationsanimal modelsMycobacterium tuberculosispharmacodynamicsresistance suppression

Identifiers

PMID32958720
PMCPMC7674066
OpenAlexW3087668221

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.